135 related articles for article (PubMed ID: 22380773)
1. Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening.
Kotraiah V; Pallares D; Toema D; Kong D; Beausoleil E
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):489-94. PubMed ID: 22380773
[TBL] [Abstract][Full Text] [Related]
2. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism.
Chiu CC; Yeh TH; Lai SC; Wu-Chou YH; Chen CH; Mochly-Rosen D; Huang YC; Chen YJ; Chen CL; Chang YM; Wang HL; Lu CS
Exp Neurol; 2015 Jan; 263():244-53. PubMed ID: 25263579
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA
Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664
[TBL] [Abstract][Full Text] [Related]
5. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
Wey MC; Fernandez E; Martinez PA; Sullivan P; Goldstein DS; Strong R
PLoS One; 2012; 7(2):e31522. PubMed ID: 22384032
[TBL] [Abstract][Full Text] [Related]
6. Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
Casida JE; Ford B; Jinsmaa Y; Sullivan P; Cooney A; Goldstein DS
Chem Res Toxicol; 2014 Aug; 27(8):1359-61. PubMed ID: 25045800
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice.
Stachowicz A; Olszanecki R; Suski M; Wiśniewska A; Totoń-Żurańska J; Madej J; Jawień J; Białas M; Okoń K; Gajda M; Głombik K; Basta-Kaim A; Korbut R
J Am Heart Assoc; 2014 Nov; 3(6):e001329. PubMed ID: 25392542
[TBL] [Abstract][Full Text] [Related]
8. Aldehyde dehydrogenase 2 in sporadic Parkinson's disease.
Michel TM; Käsbauer L; Gsell W; Jecel J; Sheldrick AJ; Cortese M; Nickl-Jockschat T; Grünblatt E; Riederer P
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S68-72. PubMed ID: 24262192
[TBL] [Abstract][Full Text] [Related]
9. Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant.
Perez-Miller S; Younus H; Vanam R; Chen CH; Mochly-Rosen D; Hurley TD
Nat Struct Mol Biol; 2010 Feb; 17(2):159-64. PubMed ID: 20062057
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the East Asian variant of aldehyde dehydrogenase-2: bioactivation of nitroglycerin and effects of Alda-1.
Beretta M; Gorren AC; Wenzl MV; Weis R; Russwurm M; Koesling D; Schmidt K; Mayer B
J Biol Chem; 2010 Jan; 285(2):943-52. PubMed ID: 19906643
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological activation of aldehyde dehydrogenase 2 by Alda-1 reverses alcohol-induced hepatic steatosis and cell death in mice.
Zhong W; Zhang W; Li Q; Xie G; Sun Q; Sun X; Tan X; Sun X; Jia W; Zhou Z
J Hepatol; 2015 Jun; 62(6):1375-81. PubMed ID: 25543082
[TBL] [Abstract][Full Text] [Related]
12. Aldehydic load and aldehyde dehydrogenase 2 profile during the progression of post-myocardial infarction cardiomyopathy: benefits of Alda-1.
Gomes KM; Bechara LR; Lima VM; Ribeiro MA; Campos JC; Dourado PM; Kowaltowski AJ; Mochly-Rosen D; Ferreira JC
Int J Cardiol; 2015 Jan; 179():129-38. PubMed ID: 25464432
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease.
Grünblatt E; Riederer P
J Neural Transm (Vienna); 2016 Feb; 123(2):83-90. PubMed ID: 25298080
[TBL] [Abstract][Full Text] [Related]
14. Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system.
Anderson DW; Schray RC; Duester G; Schneider JS
Brain Res; 2011 Aug; 1408():81-7. PubMed ID: 21784415
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial aldehyde dehydrogenase-2 activation prevents β-amyloid-induced endothelial cell dysfunction and restores angiogenesis.
Solito R; Corti F; Chen CH; Mochly-Rosen D; Giachetti A; Ziche M; Donnini S
J Cell Sci; 2013 May; 126(Pt 9):1952-61. PubMed ID: 23447675
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
Vanle BC; Florang VR; Murry DJ; Aguirre AL; Doorn JA
Biochem Biophys Res Commun; 2017 Oct; 492(2):275-281. PubMed ID: 28830811
[TBL] [Abstract][Full Text] [Related]
17. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
[TBL] [Abstract][Full Text] [Related]
18. Effects of Alda-1, an Aldehyde Dehydrogenase-2 Agonist, on Hypoglycemic Neuronal Death.
Ikeda T; Takahashi T; Tsujita M; Kanazawa M; Toriyabe M; Koyama M; Itoh K; Nakada T; Nishizawa M; Shimohata T
PLoS One; 2015; 10(6):e0128844. PubMed ID: 26083658
[TBL] [Abstract][Full Text] [Related]
19. Aldehyde dehydrogenase-2 activation during cardioplegic arrest enhances the cardioprotection against myocardial ischemia-reperfusion injury.
Gong D; Zhang Y; Zhang H; Gu H; Jiang Q; Hu S
Cardiovasc Toxicol; 2012 Dec; 12(4):350-8. PubMed ID: 22814936
[TBL] [Abstract][Full Text] [Related]
20. Proteomic Analysis of Mitochondria-Enriched Fraction Isolated from the Frontal Cortex and Hippocampus of Apolipoprotein E Knockout Mice Treated with Alda-1, an Activator of Mitochondrial Aldehyde Dehydrogenase (ALDH2).
Stachowicz A; Olszanecki R; Suski M; Głombik K; Basta-Kaim A; Adamek D; Korbut R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
